Scarica l'app Stockscreener
233.80
6.09%
-15.15
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché AXSM Giù?
Forum
Previsione
Axsome Therapeutics Inc Borsa (AXSM) Ultime notizie
AXSM Stock Is Rising Today After Wall Street’s Positive Stance Despite Mixed Q1 – What's Behind The Optimism? - Stocktwits
AXSM Stock In Spotlight Ahead Of Key FDA Verdict On Alzheimer’s Drug This Week - Stocktwits
Why Axsome Therapeutics (AXSM) Stock Is Down Today - Moomoo
Axsome Therapeutics’ Q4 Numbers Beat Wall Street Expectations: Analyst Sees Over 23% Upside For Stock - Stocktwits
Axsome Therapeutics (AXSM) Stock Looks Pricey On Sales Yet Fair On Value - Yahoo Finance
How Investors May Respond To Axsome Therapeutics (AXSM) Advancing Solriamfetol Into Phase 3 Pediatric ADHD Trials - Yahoo Finance
Axsome Therapeutics (AXSM) Following FOCUS 2 Dosing Is The ADHD Upside Already Priced In - Yahoo Finance
Axsome Therapeutics, Inc. $AXSM Shares Sold by Granite Investment Partners LLC - MarketBeat
Better Growth Buy: Axsome vs Revolution Medicines - The Motley Fool
Axsome Therapeutics (AXSM) Could Be 11% Undervalued Following Its Pediatric ADHD Trial Start - simplywall.st
Burney Co. Invests $1.63 Million in Axsome Therapeutics, Inc. $AXSM - MarketBeat
Is Axsome Therapeutics, Inc. (AXSM) Among the Best Under-the-Radar Stocks to Invest In? - Insider Monkey
Axsome Begins Phase III Study on Solriamfetol for ADHD in Children - Yahoo Finance
AXSM Reiterated by HC Wainwright & Co. -- Price Target Maintained at $290 - GuruFocus
Axsome Therapeutics' (AXSM) "Buy" Rating Reaffirmed at HC Wainwright - MarketBeat
H.C. Wainwright reiterates Axsome stock rating on ADHD trials - Investing.com
H.C. Wainwright reiterates Axsome stock rating on ADHD trials By Investing.com - Investing.com Canada
RBC Capital Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Raises Target Price to $304 - Moomoo
Analysts Have Conflicting Sentiments on These Healthcare Companies: HUTCHMED (HCM), Axsome Therapeutics (AXSM) and Vertex Pharmaceuticals (VRTX) - The Globe and Mail
H.C. Wainwright Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Maintains Target Price $290 - Moomoo
Mizuho Securities Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Maintains Target Price $310 - Moomoo
Axsome Therapeutics, Exelixis, Incyte Among 20 New Stocks On IBD's Premier Watchlists - Investor's Business Daily
Axsome Therapeutics doses first pediatric patient in Phase 3 ADHD study - grafa.com
RBC Capital Adjusts Axsome Therapeutics Price Target to $304 From $302, Maintains Outperform Rating - Moomoo
Axsome doses first patient in pediatric ADHD trial By Investing.com - Investing.com South Africa
Axsome Therapeutics Doses First Patient in Trial of Potential ADHD Drug - marketscreener.com
Axsome doses first patient in pediatric ADHD trial - Investing.com
Axsome Therapeutics Initiates FOCUS-2 Phase 3 Trial of Solriamfetol in Children with Attention Deficit Hyperactivity Disorder (ADHD) - The Manila Times
Axsome starts Phase 3 ADHD trial in children, enrolling 468 patients - Stock Titan
Sleep Apnea Pipeline 2026: Therapies, MOA Insights, and Key Clinical Trial Updates by DelveInsight | Apnimed, Eli Lilly, Incannex Healthcare, Axsome Therapeutics, Jazz Pharma, Bioprojet - Barchart
These 3 Stocks Trounced the S&P 500 in the First Half of 2026 -- and Wall Street Thinks 1 of Them Could Soar Even More - The Motley Fool
Axsome Therapeutics (AXSM) Stock Analysis: Unveiling a 13% Potential Upside Amid Robust Revenue Growth - DirectorsTalk Interviews
Responsive Playbooks and the AXSM Inflection - Stock Traders Daily
The Bull Case For Axsome Therapeutics (AXSM) Could Change Following Phase 3 ADHD Trial And Index Moves - simplywall.st
HB Wealth Management LLC Grows Holdings in Axsome Therapeutics, Inc. $AXSM - MarketBeat
ETFs Investing in Axsome Therapeutics, Inc. Stocks - TradingView
SG Americas Securities LLC Has $1.25 Million Stock Holdings in Axsome Therapeutics, Inc. $AXSM - MarketBeat
If You Invested $1,000 in Axsome Therapeut (AXSM) - Stock Titan
Is Axsome Therapeutics Stock a Millionaire Maker? Here's What the Numbers Say. - The Motley Fool
Axsome Therapeutics(AXSM.US) 10% Shareholder Sells US$11.93 Million in Common Stock - Moomoo
Axsome therapeutics CEO Herriot Tabuteau sells $11.9 million in shares - Investing.com UK
Form 4 Axsome Therapeutics Inc For: 1 July By Investing.com - Investing.com Canada
Axsome therapeutics CEO Herriot Tabuteau sells $11.9 million in shares By Investing.com - Investing.com South Africa
Axsome Therapeutics (AXSM) CEO sells 49,666 exercised shares under 10b5-1 plan - Stock Titan
Form 144 Axsome Therapeutics For: 1 July By Investing.com - Investing.com Canada
Form 144 | Axsome Therapeutics(AXSM.US) Officer Proposes to Sell 11.95 Million in Common Stocks - Moomoo
49,666-share sale notice for AXSM (NASDAQ: AXSM) via cashless exercise - Stock Titan
Why Axsome Stock Has Doubled In Nine Months - Yahoo! Finance Canada
Pictet Asset Management Holding SA Sells 20,080 Shares of Axsome Therapeutics, Inc. $AXSM - MarketBeat
Sleep Apnea Market Expected to Experience Accelerated Growth and Market Evolution by 2034 – DelveInsight | Apnimed, Eli Lilly, Incannex Healthcare, Axsome Therapeutics, Jazz Pharma, Bioprojet - Barchart.com
Axsome Therapeutics, Inc.(NasdaqGM: AXSM) dropped from Russell 2000 Index - marketscreener.com
Axsome Therapeutics, Inc.(NasdaqGM: AXSM) added to Russell Midcap Growth Benchmark - marketscreener.com
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Is Expected To Breakeven In The Near Future - Moomoo
Axsome Therapeutics, Inc.(NasdaqGM:AXSM) dropped from Russell 2000 Growth Benchmark - marketscreener.com
Axsome Therapeutics, Inc. (AXSM) Stock Analysis: Strong Buy Ratings Signal Potential Upside In Biotech Sector - DirectorsTalk Interviews
Axsome Therapeutics, Inc.(NasdaqGM: AXSM) added to Russell 1000 Growth Benchmark - marketscreener.com
2.64%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):